of the pandemic . the company continues to optimize its balance sheet for the current environment . in the third quarter of 2020 , the company repurchased $ 24,466,000 aggregate principal amount of its 2021 notes . earlier in the year , the company entered into separate privately negotiated agreements with certain holders to exchange an aggregate of $ 73,875,000 of its 2021 and 2022 notes into new 5 % series ii convertible senior exchange notes ( the `` series ii 2024 notes `` ) of the company . this transaction enhanced the company 's financial flexibility in reducing short-term debt by extending a significant portion of near-term convertible debt to november 2024. these actions , as well as other actions completed in the first half of 2020 , for example completing the divestiture of dynamic controls and obtaining an unsecured loan under the coronavirus aid , relief , and economic security ( `` cares `` ) act , borrowing availability under the abl revolver , and the anticipated generation of adjusted ebitda and free cash flow , should provide the company sufficient liquidity to manage the business and meet its obligations . strategy the company historically had a strategy to be a leading provider of durable medical equipment to health 43 part ii management discussion & analysis - overview care providers in global markets by providing the broadest portfolio available . this strategy has not kept pace with certain reimbursement changes , competitive dynamics and company-specific challenges . since 2015 , the company has made a major shift in its strategy . the company has since been aligning its resources to produce products and solutions that assist customers and end-users with their most clinically complex needs . by focusing the company 's efforts to provide the best possible assistance and outcomes to the people and caregivers who use its products , the company aims to improve its financial condition for sustainable profit and growth . as a result , the company is undertaking a substantial multi-year business optimization plan . business optimization efforts the company continues to execute a multi-year strategy to return the company to profitability by focusing its resources on products and solutions that provide greater healthcare value in clinically complex rehabilitation and post-acute care . the company 's business optimization actions and growth plan balance innovative organic growth , product portfolio changes across all regions , and cost improvements in supply chain and administrative functions . key elements of the business optimization and growth plans are : globally , continue to drive all business segments and product lines based on their potential to achieve a leading market position and to support profitability goals ; in europe , leverage centralized innovation and supply chain capabilities while reducing the cost and complexity of a legacy infrastructure ; in north america , adjust the portfolio to consistently grow profitability amid cost increases by adding new products , reducing costs and continuing to improve customers ' experience ; in asia pacific , remain focused on sustainable growth and expansion in the southeast asia region ; and , take actions globally to reduce working capital and improve free cash flow . as it navigates the uncertain business environment resulting from the pandemic , the company continues to allocate more resources to the business units experiencing increased demand and expects to continue taking actions to mitigate the potential negative financial and operational impacts on other parts of the company 's business that have declined . in the medium-term , the company still expects to execute on its business optimization strategy , such as the global it modernization initiative which is expected to ultimately result in optimization of the operating structure . in 2020 , the company made significant progress with improved financial performance and strengthened its overall business profile by taking actions such as : significantly reduced expenses given the reduced net sales as a result of the pandemic ; enhanced its product portfolio including the introduction of power wheelchairs with standing capabilities , power add-ons for manual wheelchairs , beds , lifts and slings , all of which are expected to drive incremental sales and expand margins ; completed the outsourcing of the it infrastructure and commenced the roll out of modernized it systems in canada and new zealand ; completed the consolidation of three german facilities ; divested dynamic controls and entered into a long-term supply agreement ; and , strengthened the balance sheet by retiring $ 24,466,000 of 2021 convertible notes and executed a convertible note exchange that effectively extended the maturity of $ 73,875,000 of convertible notes to 2024. the company made great progress in 2020 with more work to be done in 2021. the company intends to continue to make significant investments in its business improvement initiatives , may reduce sales in certain areas , refocus resources away from less accretive activities , and look at its global infrastructure for opportunities to drive efficiency with a focus on improving profitability and free cash flow generation . as part of the company 's efforts to streamline its operations and focus its resources on core product lines that provide the greatest value and financial returns , the company continuously evaluates opportunities and activities , including potential divestitures , which it considers from time to time , particularly if they involve businesses or assets outside of the company 's primary areas of focus . outlook given the continued progress of the company 's performance , increased visibility into the path of recovery for its customers , expected improved access to healthcare , and successful vaccine execution , improvements to global pandemic-related supply chain disruptions , and pent-up 44 part ii md & a - accounting estimates and pronouncements demand from the prior year , the company expects improved operating results for the full year 2021. the company participates in durable healthcare markets and serves a persistent need for its products . story_separator_special_tag sg & a expenses related to non-allocated corporate costs for 2020 decreased 7.4 % , or $ 2,137,000 , compared to 2019. the decrease was primarily driven by reduced employee-related costs , primarily stock compensation . stock compensation was lower in 2020 due to lowered projected vesting assumptions on multi-year cycle performance awards impacted by the pandemic and was partially offset by modification of performance awards in the fourth quarter of 2020. related to the asia pacific businesses , 2020 sg & a decreased 44.0 % , or $ 6,199,000 , compared to 2019 with foreign currency translation increasing sg & a expenses $ 113,000 , or 7.4 % . the divestiture of dynamic controls decreased expense by $ 3,484,000 or 24.7 % . constant currency sg & a expenses decreased $ 2,828,000 , or 26.7 % , primarily driven by reduced employee-related costs . 51 part ii md & a - sg & a 2019 versus 2018 replace_table_token_9_th consolidated sg & a expenses as a percentage of net sales were 28.0 % in 2019 and 29.0 % in 2018. the overall dollar decrease was $ 21,845,000 , or 7.7 % , with foreign currency translation decreasing expense by $ 7,228,000. excluding the impact of foreign currency translation , sg & a expenses decreased $ 14,617,000 , or 5.2 % , primarily driven by reduced employment and product liability costs partially offset by higher bonus and stock compensation expense . europe - european sg & a expenses decreased by 8.7 % , or $ 11,413,000 , in 2019 compared to 2018. foreign currency translation decreased expense by approximately $ 6,135,000 or 4.7 % . excluding the foreign currency translation impact , sg & a expenses decreased by $ 5,278,000 , or 4.0 % , primarily attributable to lower employment costs . north america - sg & a expenses for north america decreased 17.8 % , or $ 21,104,000 , in 2019 compared to 2018 with foreign currency translation decreasing expense by $ 302,000 or 0.2 % . excluding the foreign currency translation , sg & a expense decreased $ 20,802,000 , or 17.6 % , driven primarily by decreased employment , consulting and product liability costs . all other - sg & a expenses increased $ 10,672,000 in 2019 compared to 2018. foreign currency translation decreased expense by $ 791,000. all other includes sg & a related to the asia pacific businesses and non-allocated corporate costs . sg & a expenses related to non-allocated corporate costs for 2019 increased 61.3 % , or $ 11,036,000 , compared to 2018. the increase was driven primarily by increased employment costs , including stock compensation and bonus expense . related to the asia pacific businesses , 2019 sg & a decreased 2.5 % , or $ 364,000 , compared to 2018 with foreign currency translation decreasing sg & a expenses $ 791,000 , or 5.5 % . constant currency sg & a expenses increased $ 427,000 , or 3.0 % , primarily due to higher sales and marketing and employment costs . 52 part ii md & a - operating income operating income ( loss ) replace_table_token_10_th 2020 versus 2019 consolidated operating income increased by $ 21,737,000 to $ 11,327,000 in 2020 from an operating loss of $ 10,410,000 in 2019 primarily due to a $ 23,704,000 decrease in sg & a expenses , principally attributable to lower employment costs , gain on sale of dynamic controls of $ 9,790,000 and decrease in restructuring costs of $ 4,471,000 , which more than offset lower gross profit on lower sales , primarily impacted by the pandemic . europe - operating income decreased by $ 13,492,000 in 2020 compared to 2019 primarily related to lower gross profit on lower sales and unfavorable manufacturing variances , partially offset by reduced sg & a expenses , primarily driven by reduced employee-related costs . this segment was significantly impacted by the pandemic . north america - operating income increased by $ 17,041,000 in 2020 compared to 2019 driven primarily by lower sg & a expenses , due to decreased employee-related costs , as well as improved gross margin driven by product mix and cost reductions . all other - operating loss improved in 2020 compared to 2019 driven by decreased sg & a expense driven by reduced employee-related costs , primarily stock compensation expense , and improved profitability in the asia pacific business . charge related to restructuring activities the company 's restructuring charges were originally necessitated primarily by continued declines in medicare and medicaid reimbursement by the u.s. government , as well as similar healthcare reimbursement pressures abroad , which negatively affect the company 's customers ( e.g . home health care providers ) and continued pricing pressures faced by the company due to the outsourcing by competitors to lower cost locations . restructuring decisions were also the result of reduced profitability in each of the segments . in addition , as a result of the company 's business improvement strategy , additional restructuring actions have continued into 2020. the company expects reduced salary and benefit costs principally impacting selling , general and administrative expenses and costs of products sold . charges for the year ended december 31 , 2020 totaled $ 7,358,000 which were related to europe ( $ 5,934,000 ) , north america ( $ 1,306,000 ) and all other ( $ 118,000 ) . the european charges incurred related to severance ( $ 5,588,000 ) and lease termination costs ( $ 346,000 ) primarily related to the german facility consolidation . in north america , all charges incurred related to severance . all other charges were related to severance . payments for the year ended december 31 , 2020 were $ 8,132,000 and the cash payments were funded with company 's cash on hand . the majority of the 2020 accrued balances are expected to be paid out within twelve months . charges for the year ended december 31 , 2019 totaled $ 11,829,000

liquidity and capital resources the company continues to maintain an adequate liquidity position through its cash balances and unused bank lines of credit ( refer to long-term debt in the notes to the consolidated financial statements included in this report ) as described below . key balances on the company 's balance sheet and related metrics : replace_table_token_14_th ( 1 ) current assets less current liabilities . ( 2 ) long-term debt and total debt include finance leases but exclude debt issuance costs recognized as a deduction from the carrying amount of debt liability and debt discounts classified as debt or equity and operating leases . ( 3 ) reflects the combined availability of the company 's north american and european asset-based revolving credit facilities before borrowings . the change in borrowing availability is due to changes in the calculated borrowing base . at december 31 , 2020 the company had drawn $ 20,000,000 on the north american credit facility and $ 11,502,000 on the european credit facility . outstanding borrowings and availability are calculated on a month lag related to the european credit facility . the company had no borrowings on its credit facilities as of december 31 , 2019. the company 's cash and cash equivalents were $ 105,298,000 and $ 80,063,000 at december 31 , 2020 and december 31 , 2019 , respectively .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources the company continues to maintain an adequate liquidity position through its cash balances and unused bank lines of credit ( refer to long-term debt in the notes to the consolidated financial statements included in this report ) as described below . key balances on the company 's balance sheet and related metrics : replace_table_token_14_th ( 1 ) current assets less current liabilities . ( 2 ) long-term debt and total debt include finance leases but exclude debt issuance costs recognized as a deduction from the carrying amount of debt liability and debt discounts classified as debt or equity and operating leases . ( 3 ) reflects the combined availability of the company 's north american and european asset-based revolving credit facilities before borrowings . the change in borrowing availability is due to changes in the calculated borrowing base . at december 31 , 2020 the company had drawn $ 20,000,000 on the north american credit facility and $ 11,502,000 on the european credit facility . outstanding borrowings and availability are calculated on a month lag related to the european credit facility . the company had no borrowings on its credit facilities as of december 31 , 2019. the company 's cash and cash equivalents were $ 105,298,000 and $ 80,063,000 at december 31 , 2020 and december 31 , 2019 , respectively .
```    
 Suspicious Activity Report : of the pandemic . the company continues to optimize its balance sheet for the current environment . in the third quarter of 2020 , the company repurchased $ 24,466,000 aggregate principal amount of its 2021 notes . earlier in the year , the company entered into separate privately negotiated agreements with certain holders to exchange an aggregate of $ 73,875,000 of its 2021 and 2022 notes into new 5 % series ii convertible senior exchange notes ( the `` series ii 2024 notes `` ) of the company . this transaction enhanced the company 's financial flexibility in reducing short-term debt by extending a significant portion of near-term convertible debt to november 2024. these actions , as well as other actions completed in the first half of 2020 , for example completing the divestiture of dynamic controls and obtaining an unsecured loan under the coronavirus aid , relief , and economic security ( `` cares `` ) act , borrowing availability under the abl revolver , and the anticipated generation of adjusted ebitda and free cash flow , should provide the company sufficient liquidity to manage the business and meet its obligations . strategy the company historically had a strategy to be a leading provider of durable medical equipment to health 43 part ii management discussion & analysis - overview care providers in global markets by providing the broadest portfolio available . this strategy has not kept pace with certain reimbursement changes , competitive dynamics and company-specific challenges . since 2015 , the company has made a major shift in its strategy . the company has since been aligning its resources to produce products and solutions that assist customers and end-users with their most clinically complex needs . by focusing the company 's efforts to provide the best possible assistance and outcomes to the people and caregivers who use its products , the company aims to improve its financial condition for sustainable profit and growth . as a result , the company is undertaking a substantial multi-year business optimization plan . business optimization efforts the company continues to execute a multi-year strategy to return the company to profitability by focusing its resources on products and solutions that provide greater healthcare value in clinically complex rehabilitation and post-acute care . the company 's business optimization actions and growth plan balance innovative organic growth , product portfolio changes across all regions , and cost improvements in supply chain and administrative functions . key elements of the business optimization and growth plans are : globally , continue to drive all business segments and product lines based on their potential to achieve a leading market position and to support profitability goals ; in europe , leverage centralized innovation and supply chain capabilities while reducing the cost and complexity of a legacy infrastructure ; in north america , adjust the portfolio to consistently grow profitability amid cost increases by adding new products , reducing costs and continuing to improve customers ' experience ; in asia pacific , remain focused on sustainable growth and expansion in the southeast asia region ; and , take actions globally to reduce working capital and improve free cash flow . as it navigates the uncertain business environment resulting from the pandemic , the company continues to allocate more resources to the business units experiencing increased demand and expects to continue taking actions to mitigate the potential negative financial and operational impacts on other parts of the company 's business that have declined . in the medium-term , the company still expects to execute on its business optimization strategy , such as the global it modernization initiative which is expected to ultimately result in optimization of the operating structure . in 2020 , the company made significant progress with improved financial performance and strengthened its overall business profile by taking actions such as : significantly reduced expenses given the reduced net sales as a result of the pandemic ; enhanced its product portfolio including the introduction of power wheelchairs with standing capabilities , power add-ons for manual wheelchairs , beds , lifts and slings , all of which are expected to drive incremental sales and expand margins ; completed the outsourcing of the it infrastructure and commenced the roll out of modernized it systems in canada and new zealand ; completed the consolidation of three german facilities ; divested dynamic controls and entered into a long-term supply agreement ; and , strengthened the balance sheet by retiring $ 24,466,000 of 2021 convertible notes and executed a convertible note exchange that effectively extended the maturity of $ 73,875,000 of convertible notes to 2024. the company made great progress in 2020 with more work to be done in 2021. the company intends to continue to make significant investments in its business improvement initiatives , may reduce sales in certain areas , refocus resources away from less accretive activities , and look at its global infrastructure for opportunities to drive efficiency with a focus on improving profitability and free cash flow generation . as part of the company 's efforts to streamline its operations and focus its resources on core product lines that provide the greatest value and financial returns , the company continuously evaluates opportunities and activities , including potential divestitures , which it considers from time to time , particularly if they involve businesses or assets outside of the company 's primary areas of focus . outlook given the continued progress of the company 's performance , increased visibility into the path of recovery for its customers , expected improved access to healthcare , and successful vaccine execution , improvements to global pandemic-related supply chain disruptions , and pent-up 44 part ii md & a - accounting estimates and pronouncements demand from the prior year , the company expects improved operating results for the full year 2021. the company participates in durable healthcare markets and serves a persistent need for its products . story_separator_special_tag sg & a expenses related to non-allocated corporate costs for 2020 decreased 7.4 % , or $ 2,137,000 , compared to 2019. the decrease was primarily driven by reduced employee-related costs , primarily stock compensation . stock compensation was lower in 2020 due to lowered projected vesting assumptions on multi-year cycle performance awards impacted by the pandemic and was partially offset by modification of performance awards in the fourth quarter of 2020. related to the asia pacific businesses , 2020 sg & a decreased 44.0 % , or $ 6,199,000 , compared to 2019 with foreign currency translation increasing sg & a expenses $ 113,000 , or 7.4 % . the divestiture of dynamic controls decreased expense by $ 3,484,000 or 24.7 % . constant currency sg & a expenses decreased $ 2,828,000 , or 26.7 % , primarily driven by reduced employee-related costs . 51 part ii md & a - sg & a 2019 versus 2018 replace_table_token_9_th consolidated sg & a expenses as a percentage of net sales were 28.0 % in 2019 and 29.0 % in 2018. the overall dollar decrease was $ 21,845,000 , or 7.7 % , with foreign currency translation decreasing expense by $ 7,228,000. excluding the impact of foreign currency translation , sg & a expenses decreased $ 14,617,000 , or 5.2 % , primarily driven by reduced employment and product liability costs partially offset by higher bonus and stock compensation expense . europe - european sg & a expenses decreased by 8.7 % , or $ 11,413,000 , in 2019 compared to 2018. foreign currency translation decreased expense by approximately $ 6,135,000 or 4.7 % . excluding the foreign currency translation impact , sg & a expenses decreased by $ 5,278,000 , or 4.0 % , primarily attributable to lower employment costs . north america - sg & a expenses for north america decreased 17.8 % , or $ 21,104,000 , in 2019 compared to 2018 with foreign currency translation decreasing expense by $ 302,000 or 0.2 % . excluding the foreign currency translation , sg & a expense decreased $ 20,802,000 , or 17.6 % , driven primarily by decreased employment , consulting and product liability costs . all other - sg & a expenses increased $ 10,672,000 in 2019 compared to 2018. foreign currency translation decreased expense by $ 791,000. all other includes sg & a related to the asia pacific businesses and non-allocated corporate costs . sg & a expenses related to non-allocated corporate costs for 2019 increased 61.3 % , or $ 11,036,000 , compared to 2018. the increase was driven primarily by increased employment costs , including stock compensation and bonus expense . related to the asia pacific businesses , 2019 sg & a decreased 2.5 % , or $ 364,000 , compared to 2018 with foreign currency translation decreasing sg & a expenses $ 791,000 , or 5.5 % . constant currency sg & a expenses increased $ 427,000 , or 3.0 % , primarily due to higher sales and marketing and employment costs . 52 part ii md & a - operating income operating income ( loss ) replace_table_token_10_th 2020 versus 2019 consolidated operating income increased by $ 21,737,000 to $ 11,327,000 in 2020 from an operating loss of $ 10,410,000 in 2019 primarily due to a $ 23,704,000 decrease in sg & a expenses , principally attributable to lower employment costs , gain on sale of dynamic controls of $ 9,790,000 and decrease in restructuring costs of $ 4,471,000 , which more than offset lower gross profit on lower sales , primarily impacted by the pandemic . europe - operating income decreased by $ 13,492,000 in 2020 compared to 2019 primarily related to lower gross profit on lower sales and unfavorable manufacturing variances , partially offset by reduced sg & a expenses , primarily driven by reduced employee-related costs . this segment was significantly impacted by the pandemic . north america - operating income increased by $ 17,041,000 in 2020 compared to 2019 driven primarily by lower sg & a expenses , due to decreased employee-related costs , as well as improved gross margin driven by product mix and cost reductions . all other - operating loss improved in 2020 compared to 2019 driven by decreased sg & a expense driven by reduced employee-related costs , primarily stock compensation expense , and improved profitability in the asia pacific business . charge related to restructuring activities the company 's restructuring charges were originally necessitated primarily by continued declines in medicare and medicaid reimbursement by the u.s. government , as well as similar healthcare reimbursement pressures abroad , which negatively affect the company 's customers ( e.g . home health care providers ) and continued pricing pressures faced by the company due to the outsourcing by competitors to lower cost locations . restructuring decisions were also the result of reduced profitability in each of the segments . in addition , as a result of the company 's business improvement strategy , additional restructuring actions have continued into 2020. the company expects reduced salary and benefit costs principally impacting selling , general and administrative expenses and costs of products sold . charges for the year ended december 31 , 2020 totaled $ 7,358,000 which were related to europe ( $ 5,934,000 ) , north america ( $ 1,306,000 ) and all other ( $ 118,000 ) . the european charges incurred related to severance ( $ 5,588,000 ) and lease termination costs ( $ 346,000 ) primarily related to the german facility consolidation . in north america , all charges incurred related to severance . all other charges were related to severance . payments for the year ended december 31 , 2020 were $ 8,132,000 and the cash payments were funded with company 's cash on hand . the majority of the 2020 accrued balances are expected to be paid out within twelve months . charges for the year ended december 31 , 2019 totaled $ 11,829,000

